Taisho Pharmaceutical. Goldman Sachs Pharmaceutical Conference 2003 September 25, 2003

Transcription

1 Taisho Pharmaceutical Goldman Sachs Pharmaceutical Conference 2003 September 25, 2003

2 SelfMedication Business

3 Self-Medication Operation Group Pressing Issues and Prospects 1. Continuous release of a large number of new products. High expectation for RiUP for Women 2. Deregulation of the OTC drug market 3. Expanding the Livita brand (Foods for specified health use, Products for lifestylerelated diseases) 4. Products in new categories: Progress in joint development of smoking-cessation support products with GlaxoSmithKline. Step up preparation for the commercialization of products in new fields

4 FY2003 New Product Launch(Plan) <1 st Quarter> Resty Insomnia treatment Dentwell (oral care) Colac suppository-type <2 nd Quarter> Emazen Moist Form ALFE White Pabron Rhinitis Tablets S Pabron SC Pabron Troche AZ Balancer Ichoyaku Preser S Hi Series Lipovitan Wins etc. <3 rd Quarter> Nutrient drinks (Quasi-drug) New Pabron product <4 th Quarter> RiUP for women (filed for approval December 2002) New Livita products Products from Toyama Chemical Notes: Products highlighted in red are already launched. All other products are scheduled for release and are subject to change. Categories are not limited to a single product.

5 Deregulation of the OTC Drug Market Deregulation of sales channels Second round of deregulation following measures implemented in 1999 Prospects following announcement of Ministry of Health, Labour and Welfare in 2003 OTC medications desired by consumers New categories, new formulation, switchto-otc, and others

6 Deregulation of the OTC Drug Market(1) The 3rd three-year standards reform promotion plan Deregulation to allow selling OTC drugs with a relatively mild affect on the human body in general retail stores (Objections by the Ministry of Health, Labour and Welfare) Sales of OTC drugs are restricted to outlets staffed by qualified pharmacists to assist with instructions on dosage and administration with the aim of preventing excessive dosage and harmful side effects. (Implementation Policies) The current status of instructions on dosage and administration conducted at general pharmacies, drug stores and other outlets is poor. Deregulation that allows the general sale of OTC drugs with low risk of harmful effects is recommended to better meet the needs of consumers.

7 Deregulation of the OTC Drug Market(2) Comments from Ministers Nobuteru Ishihara, Minister of State (Administrative and Regulatory Reform) Deregulation based on the status quo (current classification) Chikara Sakaguchi, Minister of Health, Labour and Welfare Deregulation based on a reclassification of certain OTC drugs to quasi-drugs. Reclassification of 15 medicinal properties covering 300 items Specific candidates Relief of intestinal ailments, certain cold remedies (ointments and other drugs for external use), mouthwash, suppository laxatives, certain antiinflammatory analgesic plasters, digestive medicine, eye drops (artificial tears), other ointments, and digestive medicines that alleviate stomach ailments

8 Deregulation of the OTC Drug Market(3) Interim report relating to OTC medicationsnov., 2002) 1. Review of market scope incorporating consumer needs Preventative measures at the onset of lifestyle-related disease Improve quality of life - Hair growth, smoking-cessation support, insomnia, incontinence, obesity and others Self-examination of health Treatment of symptoms of mild illness (no acknowledged history) - Vaginal candidiasis, herpes labialis, other 2. Promote switch-to-otc products 3. Herbal medicine, use of crude drugs 4. Increase formulations

9 Taisho s Response to Changes in the Industry s Environment Address changes and at the same time expand business Reinforce brand name Reinforce brand names of proprietary products ( Increase the number of leading brand products) Acquire new brands New product launch Bolster marketing in line with changes to sales channels

10 Prescription Pharmaceutical Business

11 Taisho Toyama Pharmaceutical (TTP) Business objective Promptly establish a leading position in Japan in priority fields (infectious diseases and anti-inflammatory agents) 1. Full-fledged operations commenced in April Operating structure established in the 1 st quarter of FY03 System integration Medical Representatives (MR) reassignment, handover of responsibilities Product education 3. Increase the number of special MRs for Ancaron (from 13 to 30) 4. Synergy indicated for Clarith, Lorcam and Pentcillin

12 Strengthen Marketing Organization Implement Incentive-Based Scheme Area Area Manager, Marketing All TTP Universities, Hospitals Medical Practitioners Regular exchange of information Mutual collaboration Teleconference twice a month Information sharing MR incentives common to Taisho Pharmaceutical and Toyama Chemical

13 Lineup of Antibiotic Agents Fiscal 2003 Target: Antibiotic agent share to total Type and formulation of antibiotic agents sold by TTP Oral Injection Cephem Other 45% Antibiotic agents 55% Macrolide New quinolone Penicillin Antibacterial agent

14 Measures to Bolster Activities in the Infectious Diseases Field Implement proficiency and placement tests during the year Select 100 high-caliber MRs, implement special training Nurture high-caliber MRs in the field of infectious diseases Based on test results, implement additional training for MRs in the lower percentile Strengthen marketing capabilities through consulting (proposal of hypothesis) and promotions

15 Current TTP Medium-Term Target Antibiotic agent sales Ranking TTP 1 TTP Secure a top position through synergy and the release of new products

16 Taisho Toyama Pharmaceutical: New Drug Pipeline (August 2003) Taisho Name Application Development with Remarks <Filed> Clarith Oral antibiotic; small tablet additional formula Metligine Hypotention; rapidly disintegrating tablet additional formula Solon Anti-ulcerant; powder (half portion) additional formula <Phase2/3> Ancaron Arrhythmia; injection Sanofi-Synthelabo Taisho additional formula <Phase2> NT-702 Intermittent claudication Nissan Chemical Phase2 (U.S.) (NM-702) (atherosclerosis obliterans, spinal canal stenosis) Phase1 finished(japan) ABT-773 Oral ketolide antibiotic Abbott Lab. Postponed (overseas) <Phase1> SUN N8075 Cerebral infarction (acute) Suntory U.S. Toyama Chemical Name Application Development with Remarks <Prep. for filing> T-614 Rheumatoid arthritis (DMARDs) Eisai <Phase3> T-3811 New-type quinolone Japan:P1(injection) synthetic antibacterial (oral/injection) <Phase2> T-588 Alzheimer's disease

17 Taisho original compounds: Entering Clinical Trial Stage FY2003 TS-011(Stroke) TS-021(Type II diabetes) TS-022(atopic dermatitis) FY2004 Depression/Anxiety Sleeping disorder Type I&II diabetes New drugs entering Phase I by Taisho. Underlines: starting Phase I in Japan first. Addition to these compounds, expecting entering Phase I trial of MGS0028 (by Merck) and CRA compounds (by Janssen).